A single injection into one tumor erased cancer across the entire body in early trials, offering real hope against deadly diseases without the government overreach that plagues other healthcare schemes.
Story Highlights
- Rockefeller University’s 2141-V11 antibody shrank tumors in 6 of 12 phase 1 patients, with complete remission in 2 cases of melanoma and breast cancer.
- Local injection triggered body-wide “abscopal effect,” destroying non-injected tumors by transforming them into immune-rich structures.
- Mild side effects only, unlike past CD40 therapies that caused severe toxicity from systemic delivery.
- Ongoing trials expand to nearly 200 patients with bladder, prostate, and glioblastoma cancers.
Breakthrough in Phase 1 Trials
Researchers at Rockefeller University injected the redesigned CD40 agonist antibody 2141-V11 directly into a single tumor in 12 patients with metastatic cancers, including melanoma, renal cell carcinoma, and breast cancer. Tumors shrank in six patients, and two achieved complete remission, with all lesions disappearing, even those not injected.
This abscopal effect activated systemic immunity, turning immunosuppressive tumors into structures resembling lymph nodes filled with T-cells, B-cells, and dendritic cells. Results appeared in Cancer Cell on March 16, 2026.
Breakthroughs like this are why sustained investment in biomedical science matters.
In an early trial, injecting immunotherapy into one tumor triggered immune responses across the body – with 50% of patients responding and some complete remissions.
Science saves lives. pic.twitter.com/V26f705tou
— Dr. Catharine Young (@DrCatharineY) March 18, 2026
Overcoming Past Failures
Decades of CD40 agonist development stalled due to severe toxicity from intravenous delivery, as these receptors exist broadly on healthy cells. Rockefeller’s Leonard Wagner Laboratory engineered 2141-V11 for greater potency and localized intratumoral injection, minimizing off-target effects to mild reactions only.
Preclinical work optimized this approach, proving safer activation of anti-tumor immunity. Phase 1 confirmed safety across dosing levels, distinguishing it from earlier failed trials.
Jeffrey Ravetch, Rockefeller professor, led the engineering and noted the rarity of local injection yielding systemic responses. Juan Osorio, first author and Memorial Sloan Kettering oncologist, observed tumors becoming full of immune cells like lymph nodes, even in distant sites.
This builds on immunotherapy gains, such as checkpoint inhibitors boosting metastatic melanoma five-year survival from 16% to 35%.
Expert Insights and Validation
Osorio highlighted tertiary lymphoid structures forming in injected and non-injected tumors, driving immune infiltration linked to better outcomes. Ravetch emphasized the unprecedented whole-body response from one-site treatment.
Antoni Ribas from UCLA noted prior advances set the stage for such innovations. No severe toxicities emerged, unlike prior CD40 drugs, with data consistent across sources.
Ongoing phase 1/2 trials at Memorial Sloan Kettering and Duke involve nearly 200 patients testing 2141-V11 in bladder, prostate, and glioblastoma cancers. Researchers analyze T-cell clonality to identify responders. Short-term, it validates targeted delivery for safer therapy; long-term, it could shift treatment for metastatic solid tumors if later phases succeed.
New Cancer Immunotherapy Killed Whole Tumors
Researchers at Rockefeller University are reporting encouraging results from an early clinical trial of a redesigned cancer immunotherapy that is injected directly into tumors.
In the small study, six of 12 patients experienced…
— NENE'S MOMMA (@DebrulerTerri) March 18, 2026
Implications for Patients and Innovation
Affected patients with aggressive cancers gain a promising option targeting “cold” tumors resistant to systemic therapies. Economically, localized delivery may cut costs versus broad treatments. Socially, it fuels hope amid 2026 immunotherapy-driven survival rates reaching 70% in some cases.
Politically, under President Trump’s focus on American innovation, such academic breakthroughs counter past overspending on inefficient programs, prioritizing real results for families fighting cancer. Oncology advances spur CD40 combo trials, reshaping markets beyond blood cancers.
Sources:
Scientists inject one tumor and watch cancer vanish across the body
New cancer therapy hunts and destroys deadly tumors in major breakthrough: study
Immunotherapy drug eliminates aggressive cancers in clinical trial
Immunotherapy Breakthroughs: How the Body’s Own Defenses Are Changing Cancer Treatments
